Navigation Links
Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), the leading developer and manufacturer of precision guided therapy tools designed to enhance the treatment of coronary and peripheral vascular disease, today announced the signing of a supply agreement with ev3, a Covidien company, under which Volcano will supply its proprietary Intravascular Ultrasound (IVUS) technology for use in ev3's Plaque Excision Systems.  Utilizing the digital IVUS transducer incorporated in Volcano's market leading EagleEye® catheter product line, this new product will be capable of running on Volcano's global installed base of 5,000 systems.

"At Volcano, our imaging and physiology tools provide a level of precision that angiography alone simply cannot match," commented Scott Huennekens, President and CEO of Volcano. "In addition to our internally developed image guided therapy products, such as the VIBE® RX Imaging Balloon (commercially available in the EU only), we have looked to other medical device industry leaders to join us in differentiating therapeutic devices by adding integrated imaging capabilities. Covidien is an innovative company that recognizes the value of onboard visualization and is committed to bringing these new, more precise therapies to market to help improve patient outcomes. This agreement also exemplifies the value of our one system, many solutions strategy facilitated by our multi-modality platform."

Plaque Excision Systems, also called atherectomy devices, are catheters that remove plaque that blocks arteries and interrupts blood flow.  Instead of compressing plaque against the vessel wall – as is the case with balloon and stent therapy alone – plaque excision systems remove the obstruction from the vessel, thereby restoring blood flow, reducing damage to the vessel wall, and preserving future treatment options. IVUS integration offers advantages in immediate assessment of the plaque to better guide therapy.  

Over 270,000 atherectomy procedures have been performed with the market leading SilverHawk® and TurboHawk™ directional atherectomy catheters, uniquely designed to direct the therapy specifically to the diseased portion of the vessel while avoiding healthy portions of the vessel. The latest generation of TurboHawk plaque excision catheters are designed to remove all plaque morphologies from diseased arteries, including calcified lesions.    

"By partnering with Volcano, we continue to lead atherectomy therapy, enabling physicians to visualize the diseased portion of the artery for optimal plaque excision," said Stacy Enxing Seng, President, Peripheral Vascular, Covidien.  "This is particularly important as we believe preparing and treating the vessel for drug delivery, whether via drug coated balloon or stent, will create a breakthrough in treating lower extremity peripheral arterial disease."

About Volcano Corporation

Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive.  Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements.  Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  Any statements in this release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies, growth strategies, timing and achievement of product development milestones, the impact and benefits of market development, product introductions, unexpected new data, safety and technical issues, market conditions, dependence on third parties, and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our  recent annual report on Form 10-K. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
2. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
3. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
4. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
5. Volcano Corporation Announces Litigation Status
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
8. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
9. Volcano Announces Installed Base Growth Milestone
10. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
11. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):